Lenalidomide plus donor-lymphocytes infusion after allogeneic stem-cell transplantation with reduced-intensity conditioning in patients with high-risk multiple myeloma-Reference-Cited by-同舟云学术

Lenalidomide plus donor-lymphocytes infusion after allogeneic stem-cell transplantation with reduced-intensity conditioning in patients with high-risk multiple myeloma

Published:2012-07 Issue:7 Volume:40 Page:521-527
ISSN:0301-472X
Container-title:Experimental Hematology
language:en
Short-container-title:Experimental Hematology

Author:

El-Cheikh Jean,Crocchiolo Roberto,Furst Sabine,Ladaique Patrick,Castagna Luca,Faucher Catherine,Granata Angela,Oudin Claire,Lemarie Claude,Calmels Boris,Stoppa Anne-Marie,Schiano De Colella Jean-Marc,Duran Segolene,Chabannon Christian,Blaise Didier

Publisher

Elsevier BV

Subject

Cancer Research,Cell Biology,Genetics,Hematology,Molecular Biology

Reference29 articles.

1. Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma;Maloney;Blood,2003

2. Autologous stem cell transplantation followed by a dose-reduced allograft induces high complete remission rate in multiple myeloma;Kroger;Blood,2002

3. A comparison of allografting with autografting for newly diagnosed myeloma;Bruno;N Engl J Med,2007

4. Efficacy and toxicity of low-dose escalating donor lymphocyte infusion given after reduced intensity conditioning allograft for multiple myeloma;Ayuk;Leukemia,2004

5. Donor lymphocyte infusion enhances remission status in patients with persistent disease after allografting for multiple myeloma;Kroger;Br J Haematol,2001

Cited by 36 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Adoptive cellular therapy after hematopoietic stem cell transplantation;American Journal of Hematology;2024-01-25

2. Maintenance therapy after allogeneic hematopoietic stem cell transplantation for patients with multiple myeloma;International Journal of Hematology;2023-04-15

3. Comparison of Outcomes of Donor Lymphocyte Infusions With or Without Lenalidomide in Patients with Hematological Malignancies Post Allogeneic HSCT;Indian Journal of Hematology and Blood Transfusion;2022-07-22

4. A Case Report of a 58-Year-Old Woman with a Diagnosis of High-Risk Myeloma Refractory to Multiple Line of Therapy and Treated with Selinexor, Bortezomib, and Dexamethasone Prior to Allogeneic Stem Cell Transplantation;American Journal of Case Reports;2022-03-18

5. The efficacy and safety of lenalidomide in the treatment of multiple myeloma patients after allo-hematopoietic stem-cell transplantation: a systematic review and meta-analysis;Annals of Palliative Medicine;2021-07